Interleukin-6 receptor subunit alpha

Description:

Description
  • Accession: P08887
  • Swissprot: IL6RA_HUMAN
  • Organism: Homo sapiens
  • Gene: IL6R
  • Target class: Membrane receptor

Drug Relations:

sarilumab
Sarilumab is a human recombinant monoclonal antibody of the IgG1 subclass. Sarilumab is produced by recombinant DNA technology in Chinese Hamster Ovary cell suspension culture. Sarilumab binds to both soluble and membrane-bound IL-6 receptors (sIL-6R and mIL-6R), and has been shown to inhibit IL-6-mediated signaling through these receptors. IL-6 is a pleiotropic pro-inflammatory cytokine produced by a variety of cell types including T- and B-cells, lymphocytes, monocytes, and fibroblasts. IL-6 has been shown to be involved in diverse physiological processes such as T-cell activation, induction of immunoglobulin secretion, initiation of hepatic acute phase protein synthesis, and stimulation of hematopoietic precursor cell proliferation and differentiation. IL-6 is also produced by synovial and endothelial cells leading to local production of IL-6 in joints affected by inflammatory processes such as rheumatoid arthritis. Bioactivity details MOA
tocilizumab
a humanised anti-interleukin-6 receptor monoclonal antibody Bioactivity details MOA